As a 22-year-old, amateur boxer, Bradley Donohue always burned out before the third round. As his muscles tightened, his mind would go into overdrive as he tried to plan his next move and guess his opponent's. Between rounds one day, a watching sports psychologist told him, essentially, he needed to chill: "The ring is your playground. Your playground. It's simple, hit. Hit and don't be hit."

The Federal Reserve has signaled it’s getting ready to raise interest rates in March. While this could impact mortgage rates, experts say it’s difficult to predict if they’ll steadily rise throughout the year.

The Federal Reserve has signaled it’s getting ready to raise interest rates in March. While this could impact mortgage rates, experts say it’s difficult to predict if they’ll steadily rise throughout the year.

In honor of her late brother, a professor in the school of medicine at the University of Nevada-Las Vegas is pioneering a program to help families of people with Down syndrome coordinate all aspects of their medical care.

Extreme heat is not new to Nevada, but it is getting more pronounced.

The record pace of Americans quitting their jobs in 2021 led to the term the Great Resignation. Now, a new report shows Nevada had the nation’s second-highest quit rate for employees last year.

Congressman Tom Cole (OK-04), Congresswoman Dina Titus (NV-01), Congressman Markwayne Mullin (OK-02), Senator James Inhofe (R-OK) and Senator Jacky Rosen (D-NV) today introduced the bipartisan, bicameral Medical Student Education Authorization Act, to authorize the Medical Student Education (MSE) Program for five years. The MSE Program provides grants to public institutions of higher education to expand or support graduate education for physicians in states with the most severe primary care provider shortages. First created in 2019 by Congressman Cole and Senator Inhofe, the MSE Program is currently subject to annual authorizations, which results in significant uncertainty over funding and long-term planning for funded institutions.

A 2021 research paper authored by Jeffrey Cummings, MD, ScD, and colleagues estimated the cumulative expenditures to fund Alzheimer disease (AD) clinical trials over the past quarter-century and highlighted the numerous failed attempts that continue to plague the field. Overall, excluding the recent approval of aducanumab (Aduhelm; Biogen), there have only been 5 drugs—all for symptomatic treatment only—that have achieved FDA approval for AD since 1995. An estimated $42.5 billion in private expenditures has been sunk into AD clinical trials since then, with phase 3 representing the highest stage for costs of research and development ($24.1B).